Lenalidomide Export Market Intelligence: India's 237 Suppliers Shipping to 122 Countries — TransData Nexus 2026

Q: Who are the top lenalidomide exporters from India?

The top lenalidomide exporters from India are: 1. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $481.0M (54.5% market share); 2. EUGIA PHARMA SPECIALITIES LIMITED — $172.0M (19.5% market share); 3. DR REDDYS LABORATORIES LIMITED — $130.7M (14.8% market share); 4. CIPLA LIMITED — $81.9M (9.3% market share); 5. RELIANCE LIFE SCIENCES PRIVATE LIMITED — $8.3M (0.9% market share). Together they account for 98.9% of India's total lenalidomide export value.

Q: What is the total export value of lenalidomide from India?

The total export value of lenalidomide from India is $883.1M USD, recorded across 2,724 shipment transactions from 237 active exporters to 122 destination countries. The average shipment value is $324.2K.

Q: Which countries import lenalidomide from India?

India exports lenalidomide to 122 countries worldwide. The top importing countries are: UNITED STATES (96.7% share, $853.7M), JAPAN (0.6% share, $5.5M), NETHERLANDS (0.4% share, $3.8M), CANADA (0.4% share, $3.8M), COLOMBIA (0.4% share, $3.1M). These five markets account for 98.5% of total export value.

Q: What is the HS code for lenalidomide exports from India?

The primary HS code for lenalidomide exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of lenalidomide exports from India?

The average unit price for lenalidomide exports from India is $134.82 USD per unit, with prices ranging from $0.01 to $12274.09 depending on formulation, packaging, and order volume. The total market is valued at $883.1M across 2,724 shipments.

Q: Which ports handle lenalidomide exports from India?

The primary ports for lenalidomide exports from India are SAHAR AIR CARGO ACC (INBOM4) (27.2% of shipments), SAHAR AIR (25.3% of shipments), DELHI AIR CARGO ACC (INDEL4) (6.9% of shipments), Bombay Air (6.6% of shipments), DELHI AIR (5.1% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of lenalidomide?

India is one of the world's leading exporters of lenalidomide due to its large base of 237 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports lenalidomide to 122 countries, demonstrating 63% global market coverage.

Q: What certifications do Indian lenalidomide exporters need?

Indian lenalidomide exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import lenalidomide from India?

There are 557 registered buyers importing lenalidomide from India, spread across 122 countries. The repeat buyer rate is 63.4%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top lenalidomide supplier from India?

SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading lenalidomide exporter from India with a market share of 54.5% and total export value of $481.0M across 144 shipments. The top 5 suppliers together control 98.9% of total export value.

Suresh Sormare

Lenalidomide

India Pharmaceutical Trade Intelligence

$883.1M237 Suppliers122 CountriesHS 30049049

ExportsIndia → UNITED STATES96.7%India → JAPAN0.6%

ImportsUNITED STATES → India$1.6M SWITZERLAND → India$1.3M

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: SUN PHARMACEUTICAL

Lenalidomide Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Lenalidomide to the World

Between 2022 and 2026, India exported $883.1M worth of lenalidomide across 2,724 verified shipments to 122 countries — covering 63% of world markets in the Advanced Oncology segment. The largest destination is UNITED STATES (96.7%). SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 54.5% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Lenalidomide export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Lenalidomide export data snapshot — $883.1M · 237 exporters · 122 countriesTransData Nexus · Indian Customs Data

Top Lenalidomide Exporters from India

237 active exporters · Ranked by export value

View all 237 →

Top Lenalidomide Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$481.0M	144	6	54.5%
2	EUGIA PHARMA SPECIALITIES LIMITED

Top Countries Importing Lenalidomide from India

122 destination markets · Ranked by import value

All 122 countries →

Top Countries Importing Lenalidomide from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$853.7M	96.7%
2	JAPAN	$5.5M	0.6%
3	NETHERLANDS	$3.8M	0.4%
4	CANADA	$3.8M	0.4%
5	COLOMBIA	$3.1M	0.4%
6	BELGIUM	$2.5M	0.3%
7	MOROCCO	$1.1M	0.1%
8	AUSTRALIA	$1.1M	0.1%
9	MALTA	$1.0M	0.1%
10	TURKEY	$836.3K	0.1%

UNITED STATES is India's largest lenalidomide export destination, absorbing 96.7% of total exports worth $853.7M. The top 5 importing countries — UNITED STATES, JAPAN, NETHERLANDS, CANADA, COLOMBIA — together account for 98.5% of India's total lenalidomide export value. The remaining 117 destination countries collectively receive the other 1.5%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Lenalidomide to India?

15 origin countries · Total import value: $3.8M

India imports lenalidomide from 15 countries with a combined import value of $3.8M. The largest supplier is UNITED STATES ($1.6M, 12 shipments), followed by SWITZERLAND and MALTA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Lenalidomide to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$1.6M	12	40.9%
2	SWITZERLAND	$1.3M	17	34.8%
3	MALTA	$286.0K	7	7.5%
4	BRAZIL	$249.7K	4	6.5%
5	UNITED KINGDOM	$235.1K	9	6.1%
6	MEXICO	$44.3K	2	1.2%
7	IRELAND	$41.3K	3	1.1%
8	CHINA	$34.9K	4	0.9%
9	GERMANY	$20.6K	2	0.5%
10	JAPAN	$12.6K	1	0.3%

Showing top 10 of 15 origin countries

UNITED STATES is the largest supplier of lenalidomide to India, accounting for 40.9% of total import value. The top 5 origin countries — UNITED STATES, SWITZERLAND, MALTA, BRAZIL, UNITED KINGDOM — together supply 95.9% of India's lenalidomide imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Lenalidomide

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, lenalidomide is approved for the treatment of multiple myeloma and myelodysplastic syndromes. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for lenalidomide, indicating a competitive generic market. The high concentration of exports to the U.S. underscores the importance of compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Indian exporters must ensure rigorous quality control and regulatory compliance to maintain market access.

2EU & UK Regulatory Framework

In the European Union, lenalidomide has been subject to various regulatory actions. For instance, on June 8, 2023, the European Commission withdrew the marketing authorization for Lenalidomide Krka d.d. at the request of the marketing authorization holder, KRKA, d.d., Novo mesto, due to commercial reasons. This withdrawal does not preclude the presence of other generic versions of lenalidomide in the EU market. Manufacturers exporting to the EU and UK must comply with the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) requirements, including obtaining marketing authorizations and adhering to EU Good Manufacturing Practice (GMP) standards.

3WHO Essential Medicines & Global Standards

Lenalidomide is included in the WHO Model List of Essential Medicines, reflecting its importance in treating priority health conditions. The WHO Model List serves as a guide for countries to develop their own national essential medicines lists, ensuring the availability of critical medications. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to meet global quality expectations.

4India Regulatory Classification

In India, lenalidomide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. Manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations.

5Patent & Exclusivity Status

The patent landscape for lenalidomide has evolved, with original patents held by Celgene Corporation expiring, leading to increased generic competition. This has facilitated the entry of multiple generic manufacturers into the market, intensifying competition and potentially impacting pricing and market dynamics.

6Recent Industry Developments

In May 2025, the WHO convened the 25th Expert Committee on Selection and Use of Essential Medicines to update the Model List of Essential Medicines, reflecting the latest therapeutic advancements and public health priorities. In April 2025, the WHO launched the National Essential Medicines Lists (nEMLs) repository, a centralized digital platform compiling 150 national essential medicines lists from six global regions, enhancing access to critical healthcare data. In February 2025, the WHO published the 24th edition of the Model List of Essential Medicines, providing updated guidance on essential medicines for countries worldwide. In July 2023, the WHO released the 23rd edition of the Model List of Essential Medicines, reflecting the latest evidence-based recommendations for essential medicines. In March 2026, the WHO published a list of National Regulatory Authorities (NRAs) operating at maturity levels 3 and 4, indicating their capacity to ensure the quality, safety, and efficacy of medicines.

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape and the importance of staying informed about global standards and guidelines.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Lenalidomide

Retail & reference prices across 9 markets vs. India FOB export price of $134.82/unit

Global Price Benchmark for Lenalidomide across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$700–$900	USD	The U.S. market experiences high lenalidomide prices due to patent protections and limited generic competition.
United Kingdom	Approximately $750	GBP	Pricing in the UK is influenced by the British National Formulary and NHS negotiations.
Germany	Data not available	EUR	Specific pricing data for Germany is not readily accessible.
Australia	Approximately $400

Supply Chain Risk Assessment — Lenalidomide

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and intermediates essential for Active Pharmaceutical Ingredient (API) production. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in this sector. This dependency poses significant risks, as any disruption in China's supply chain can directly impact India's API manufacturing capabilities.

Recent environmental regulations in China have led to the shutdown of numerous chemical manufacturing facilities, causing supply chain disruptions. For instance, in February 2019, over 140 API manufacturers in the Beijing-Tianjin-Hebei region ceased operations due to effluent violations. Such events underscore the vulnerability of India's pharmaceutical supply chain to external regulatory changes and highlight the need for diversification in sourcing raw materials.

2Supplier Concentration & Single-Source Risk

The export market for Lenalidomide from India is highly concentrated, with the top five exporters accounting for 98.9% of total exports. SUN PHARMACEUTICAL INDUSTRIES LIMITED alone holds a 54.5% share, amounting to $481.0 million USD. This high concentration increases the risk of supply disruptions, as any operational issues within these key companies could significantly impact global supply.

Access Complete Lenalidomide Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,724 transactions across 122 markets.

Request Demo View Pricing

Frequently Asked Questions — Lenalidomide Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top lenalidomide exporters from India?

The leading lenalidomide exporters from India are SUN PHARMACEUTICAL INDUSTRIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, DR REDDYS LABORATORIES LIMITED, and 11 others. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 54.5% market share ($481.0M). The top 5 suppliers together control 98.9% of total export value.

What is the total export value of lenalidomide from India?

The total export value of lenalidomide from India is $883.1M, recorded across 2,724 shipments from 237 active exporters to 122 countries. The average shipment value is $324.2K.

Which countries import lenalidomide from India?

India exports lenalidomide to 122 countries. The top importing countries are UNITED STATES (96.7%), JAPAN (0.6%), NETHERLANDS (0.4%), CANADA (0.4%), COLOMBIA (0.4%), which together account for 98.5% of total export value.

What is the HS code for lenalidomide exports from India?

The primary HS code for lenalidomide exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Lenalidomide

Lenalidomide

Top Lenalidomide Exporters from India

Top Countries Importing Lenalidomide from India

Who Supplies Lenalidomide to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Lenalidomide

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Lenalidomide

Supply Chain Risk Assessment — Lenalidomide

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Lenalidomide Trade Intelligence

Frequently Asked Questions — Lenalidomide Exports from India

Who are the top lenalidomide exporters from India?

What is the total export value of lenalidomide from India?

Which countries import lenalidomide from India?

What is the HS code for lenalidomide exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of lenalidomide exports from India?

Which ports handle lenalidomide exports from India?

Why is India a leading exporter of lenalidomide?

What certifications do Indian lenalidomide exporters need?

How many buyers import lenalidomide from India?

What is the market share of the top lenalidomide exporter from India?

Analysis Methodology